Nigeria Launches Historic Bi-Annual HIV Prevention Injection to Accelerate 2030 National AIDS Eradication Goals

Nigeria introduces Lenacapavir, a twice-yearly HIV prevention injection, to boost adherence and reach 2030 AIDS eradication targets across eight pilot states.

By: AXL Media

Published: Mar 23, 2026, 10:24 AM EDT

Source: The information in this article was sourced from The Independent

A Shift From Daily Pills to Bi-Annual Protection

The Federal Government of Nigeria has introduced a transformative long-acting injectable for HIV prevention, marking a significant departure from traditional daily oral regimens. During a media engagement in Abuja, the Minister of State for Health and Social Welfare, Iziaq Adekunle Salako, detailed the deployment of Lenacapavir, also known as Len PrEP. This innovative treatment is designed to offer a more convenient and effective alternative for individuals at risk, requiring only two administrations annually. By reducing the frequency of dosing, the government aims to eliminate the common barriers associated with daily medication, such as pill fatigue and social stigma, which have previously hindered national prevention efforts.

Strategic Framework and Policy Readiness for National Rollout

According to Salako, the launch of this medical breakthrough follows an extensive period of preparatory work conducted by the National AIDS, Viral Hepatitis and STIs Control Programme. The ministry has overseen comprehensive policy reviews, secured necessary regulatory approvals, and finalized the procurement of commodities to ensure a seamless implementation. Pilot states were selected based on rigorous data-driven analysis to identify areas where the impact on public health would be most immediate. The minister emphasized that this structured approach is essential for expanding access to prevention services and moving the nation closer to its goal of ending the AIDS epidemic by 2030.

Enhancing Clinical Adherence and Reducing Resistance

The clinical advantages of the twice-yearly injection extend beyond convenience to include improved patient outcomes and long-term public health safety. Charles Nzelu, the Director of Public Health, noted that the introduction of Lenacapavir is expected to significantly improve adherence rates among vulnerable groups. By removing the burden of daily pill consumption, the health ministry anticipates a marked decrease in the risk of drug resistance, which often occurs when patients miss consecutive doses of oral PrEP. This shift in service delivery is viewed by experts as a critical update to the national health strategy, ensuring that preventive measures remain robust and reliable over time.